Status:
RECRUITING
Cognitive Health in Ageing Register: Investigational and Observational Trial Studies in Dementia Research (CHARIOT): Prospective Readiness Cohort (PRO) Longitudinal Study
Lead Sponsor:
Imperial College London
Conditions:
Alzheimer's Disease (AD)
Eligibility:
All Genders
65+ years
Brief Summary
Alzheimer's disease is a degenerative condition affecting the brain and is the most frequent form of dementia in older adults. Dementia is currently a major healthcare issue in the UK, affecting appro...
Detailed Description
The aim of the study is to prospectively evaluate factors and markers associated with varying cognitive performance and longitudinal trajectories in individuals with differing levels of brain amyloid ...
Eligibility Criteria
Inclusion
- To be eligible, participants must meet all inclusion criteria for the study, as follows:
- Male or Female, aged \>65years
- Willing and having capacity (as assessed according to MCA 2005) to provide written informed consent and to participate in the study, OR (if lacking capacity) has a nominated consultee (as described in the MCA 2005 and Chapter 11 of the MCA Code of Practice 2007) who is able to advise that this is what the participant would have wished.
- Have completed CPSS1 amyloid screening using either amyloid PET scanning or CSF Aβ42 measurement.
- Be fluent in and able to read and write in English and have adequate hearing and visual acuity to complete the required psychometric tests.
- Be willing and able to adhere to the study visits and assessments specified in this protocol, and the reasonable requests and expectations of the study staff.
- Have a reliable informant - study partner (relative, partner, or friend) who is willing to provide their informed consent to participate, as a source of information. The study partner must be over 18 years old and should be fluent in and able to read and write in English. The informant must have sufficient contact with the participant and sufficient cognitive ability such that the Investigator feels that they can provide meaningful information about the participant's daily functioning. At a minimum, they must be in contact with the participant at least twice per month (in person, via telephone or other audio/visual communication). The study partner will be required in-person at the V1 visit. However, they can complete all subsequent visits remotely, or in-person if required.
Exclusion
- To be eligible, participants must not meet any of the exclusion criteria for the study, as follows:
- Participant has any disability that would prevent completion of study procedures or assessments (e.g. blindness or significant visual impairment, deafness or significant hearing impairment, speech impairment, or sensory or motor dysfunction), or has any condition or situation/circumstance for which, in the opinion of the investigator, participation would not be in the best interest of the participant (e.g. compromise the participant's well-being), or that could prevent, limit, or confound the results of protocol-specified assessments and cognitive testing.
- Unable to comply with the study-specific requirements.
- History of alcohol or drug dependence or abuse, as defined by the most current version of the DSM criteria within the last 3 years.
Key Trial Info
Start Date :
March 17 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 1 2029
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT06953167
Start Date
March 17 2025
End Date
February 1 2029
Last Update
May 1 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Imperial College London
London, United Kingdom